# 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk

> **NCT05385549** · PHASE2 · RECRUITING · sponsor: **Asan Medical Center** · enrollment: 35 (estimated)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Imatinib Mesylate

## Key facts

- **NCT ID:** NCT05385549
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-07
- **Primary completion:** 2030-04-30
- **Final completion:** 2030-04-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05385549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05385549, "5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05385549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*